Barclays lowered the firm’s price target on Neurocrine to $125 from $135 and keeps an Overweight rating on the shares. The analyst expects investor focus to shift to the pipeline congenital adrenal hyperplasia pathway and Muscarinic.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Xenon reports Neurocrine will not continue development of NBI-921352
- Neurocrine reports positive results of Ingrezza in chorea study
- Neurocrine price target raised to $170 from $165 at Oppenheimer
- Neurocrine price target raised to $116 from $113 at Mizuho
- Neurocrine price target raised to $128 from $123 at RBC Capital